Shanghai Plamsa was originated from the biopharmaceutical business of Shanghai Institute of Biological Products Co., Ltd. Located in 350 Anshun Road, Changning District, Shanghai, Shanghai Plasma has a long history of blood product manufacturing. In the 1960s, Shanghai Plamsa was the first in China to use low-temperature ethanol plasma protein separation technology to manufacture human albumin and human immunoglobulin; In 1991, a modern blood product production line was introduced into China from Japan by Shanghai Plamsa, which has became the most invested, largest production scale, and most advanced technological transformation project in the history of biological product industry of China. The production line was also one of the largest in Asia at that time; In 1998, it passed the national GMP certification, which was one of the earliest in China; In 2019, it was recognized as a high-tech enterprise.

In 2022,  Shanghai Plasma established Sinopharm Kunming Plasma-derived Biotherapies Co., Ltd(referred to as "Kunming Plasma") in the manner of split-off. Kunming Plasma is located at No. 3696 Zhongning Road, Dianzhong New Area, Yunnan Province, with a designed annual plasma fractionation capacity of over 1200 tons and an estimated total investment of 2.7 billion yuan. While serving the market demand of Yunnan Province, Kunming Plasma aims to build a high-end biopharmaceutical manufacturing center for South Asia and Southeast Asia. In 2022, it has built an internationally leading and domestically first-class intelligent manufacturing factory for blood product manufacturing. Once in formal operation, it will become one of the largest blood product research and production bases in Asia.